400-859-2883
Your location:Home >News center >Industry News

Industry News

09-212022

Bispecific Antibodies – Fast Growing The…

What are bispecific antibodies, how do they work and how many bispecific antibodies are approved.

Bispecific Antibodies – Fast Growing Therapies
09-202022

PROTAC Molecule For Acute Lymphoblastic L…

Using a proteolysis targeting chimera (PROTAC) approach, researchers have developed a series of LCK degraders for the fight against acute lymphoblastic leukemia (ALL).

PROTAC Molecule For Acute Lymphoblastic Leukemia (ALL)
09-142022

Ongoing Investigation of Weight Loss Ther…

Overview of weight loss drug approved and in clinical trials, and future trends analysis.

Ongoing Investigation of Weight Loss Therapies: 3 Positive Trends
09-132022

From ADC (Antibody-Drug Conjugate) to PDC…

PDC (Peptide Drug Conjugate), as a new type of conjugated drug, has also begun to attract attention in the research and development field due to its unique advantages.

From ADC (Antibody-Drug Conjugate) to PDC (Peptide-Drug Conjugate)
08-302022

Application of PROTAC In The New Field of…

Researchers developed a live attenuated influenza A virus vaccine using proteolysis targeting chimera (PROTAC) technology to degrade viral proteins through the endogenous ubiquitin-proteasome…

Application of PROTAC In The New Field of Attenuated Vaccines
08-192022

Trodelvy: Any Chance Against Dato-DXd and…

Here, we will discuss what are the advantages of Trodelvy, and which is superior in the field of breast cancer treatment, Trodelvy vs. Dato-DXd, Enhertu?

Trodelvy: Any Chance Against Dato-DXd and Enhertu?